Compare Stocks: AKBA, CVAC, FTH, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.97 -6.0%	$1.12	$0.81 ▼ $3.20	$268.24M	0.19	4.50 million shs	2.98 million shs
AVTX Avalo Therapeutics	$18.60 -5.7%	$19.14	$9.54 ▼ $24.27	$997.79M	0.78	1.14 million shs	321,093 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FTH Sensei Biotherapeutics	$36.78 -6.2%	$30.48	$7.45 ▼ $42.14	$954.32M	-0.28	215,123 shs	94,132 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+5.67%	+9.03%	+13.20%	+18.00%	-67.09%
AVTX Avalo Therapeutics	+2.50%	+4.01%	+7.59%	+50.46%	+72.74%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-12.90%
FTH Sensei Biotherapeutics	-2.12%	+13.59%	+60.72%	+3,919,999,900.00%	+3,919,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.97 -6.0%	$1.12	$0.81 ▼ $3.20	$268.24M	0.19	4.50 million shs	2.98 million shs
AVTX Avalo Therapeutics	$18.60 -5.7%	$19.14	$9.54 ▼ $24.27	$997.79M	0.78	1.14 million shs	321,093 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FTH Sensei Biotherapeutics	$36.78 -6.2%	$30.48	$7.45 ▼ $42.14	$954.32M	-0.28	215,123 shs	94,132 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+5.67%	+9.03%	+13.20%	+18.00%	-67.09%
AVTX Avalo Therapeutics	+2.50%	+4.01%	+7.59%	+50.46%	+72.74%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-12.90%
FTH Sensei Biotherapeutics	-2.12%	+13.59%	+60.72%	+3,919,999,900.00%	+3,919,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.43	Hold	$3.90	302.89% Upside
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	142.54% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
FTH Sensei Biotherapeutics	2.86	Moderate Buy	$55.00	49.56% Upside

Current Analyst Ratings Breakdown

Latest AKBA, CVAC, FTH, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	FTH Sensei Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.50
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.14	N/A	N/A	$0.12 per share	8.07
AVTX Avalo Therapeutics	$59K	16,902.54	N/A	N/A	$4.49 per share	4.14
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A

Latest AKBA, CVAC, FTH, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
AVTX Avalo Therapeutics	N/A	19.31	19.31
CVAC CureVac	0.03	3.70	3.69
FTH Sensei Biotherapeutics	N/A	19.69	19.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVTX Avalo Therapeutics	87.06%
CVAC CureVac	17.26%
FTH Sensei Biotherapeutics	10.50%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
AVTX Avalo Therapeutics	4.46%
CVAC CureVac	2.15%
FTH Sensei Biotherapeutics	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	277.11 million	265.19 million	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable

AKBA, CVAC, FTH, and AVTX Headlines

Recent News About These Companies

TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating

29 minutes ago | marketscreener.comM

Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by TD Cowen

4 hours ago | marketbeat.com

Sensei Biotherapeutics (NASDAQ:FTH) Sets New 1-Year High - Here's Why

September 8 at 9:39 AM | marketbeat.com

Bank of America Corp DE Raises Holdings in Sensei Biotherapeutics, Inc. $FTH

September 6 at 3:27 AM | marketbeat.com

Sensei Biotherapeutics (NASDAQ:FTH) Hits New 12-Month High - Time to Buy?

September 2, 2026 | marketbeat.com

144,404 Shares in Sensei Biotherapeutics, Inc. $FTH Acquired by Alyeska Investment Group L.P.

September 2, 2026 | marketbeat.com

Sensei Biotherapeutics (NASDAQ:FTH) Shares Up 5.4% - Time to Buy?

September 1, 2026 | marketbeat.com

What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?

September 1, 2026 | zacks.com

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

September 1, 2026 | businesswire.com

Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 4.4% - Here's Why

August 31, 2026 | marketbeat.com

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Sensei Biotherapeutics (NASDAQ:FTH) Trading Up 5.3% - Still a Buy?

August 24, 2026 | marketbeat.com

Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know

August 24, 2026 | zacks.com

Sensei Biotherapeutics (NASDAQ:FTH) Upgraded by Wall Street Zen to Hold Rating

August 22, 2026 | marketbeat.com

Needham & Company LLC Initiates Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

August 21, 2026 | marketbeat.com

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

August 17, 2026 | businesswire.com

Sensei Biotherapeutics (NASDAQ:FTH) Trading Up 10.5% - What's Next?

August 14, 2026 | marketbeat.com

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

August 14, 2026 | businesswire.com

Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues

August 11, 2026 | seekingalpha.com

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 7, 2026 | businesswire.com

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

August 4, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, CVAC, FTH, and AVTX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.97 -0.06 (-6.02%)

As of 02:11 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Avalo Therapeutics NASDAQ:AVTX

$18.60 -1.12 (-5.66%)

As of 02:11 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/8/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Sensei Biotherapeutics NASDAQ:FTH

$36.78 -2.43 (-6.19%)

As of 02:10 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, CVAC, FTH, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, CVAC, FTH, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, CVAC, FTH, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, CVAC, FTH, and AVTX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Sensei Biotherapeutics NASDAQ:FTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, CVAC, FTH, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, CVAC, FTH, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, CVAC, FTH, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, CVAC, FTH, and AVTX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Sensei Biotherapeutics NASDAQ:FTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools